PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, has entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-pronged approach to accelerate the commercialization of PURE's unique and proprietary SDC-based products.
The strategic collaboration agreement provides:
ICC licenses from PURE its patents and technology know-how for the exclusive manufacture for PURE of all SDC-based products.
ICC will invest in plant improvements to allow for expanded SDC production.
ICC's R&D team will collaborate on SDC product line development.
ICC licenses the distribution rights for SDC-based products into its core businesses of institutional cleaning and sanitation products.
ICC will develop a new initiative focused on US hospital, healthcare and medical facilities.
PURE earns royalty income on SDC-products sold by ICC and its affiliates.
